中国医院用药评价与分析2017，Vol.17Issue(12)：1636-1637,1640,3.DOI:10.14009/j.issn.1672-2124.2017.12.017
水飞蓟宾联合恩替卡韦治疗乙型病毒性肝炎肝硬化的疗效观察
Observation on Efficacy of Silibinin Combined with Entecavir in Treatment of Liver Cirrhosis of Hepatitis B
孙燕燕 1郭英 1季伟1
作者信息
- 1. 宁夏回族自治区人民医院/西北民族大学第一附属医院感染科,宁夏银川 750001
- 折叠
摘要
Abstract
OBJECTIVE: To probe into the clinical efficacy of silibinin combined with entecavir in treatment of liver cirrhosis of hepatitis B .METHODS:72 patients with liver cirrhosis of hepatitis B admitted into Ningxia People 's Hospital from Jan.2016 to Jan.2017 were selected and divided into observation group and control group via random number table , with 36 cases in each .The control group was treated with entecavir , while the observation group was given silibinin based on the control group .The liver function indicators , liver fibrosis indicators and incidence of adverse drug reactions of two groups were observed .RESULTS: After treatment , levels of alanine aminotransferase , prothrombin time , serum total bilirubin and albumin of two groups were better than those of before treatment , and the observation group was better than the control group , with statistical significance ( P <0.05 ) .After treatment, the hyaluronic acid , type Ⅳprocollagen and type Ⅲprocollagen levels were better than those of before treatment , and the observation group was better than the control group , with statistical significance(P<0.05).The incidence of adverse drug reactions of observation group was 11.12％( 4/36 ) , significantly lower than that of control group [ 30.58％( 11/36 ) ] , with statistical significance ( P<0.05 ) .CONCLUSIONS:The efficacy of silibinin combined with entecavir in treatment of liver cirrhosis of hepatitis B is remarkable , which can effectively improve levels of liver function indicators and liver fibrosis indicators with fewer adverse drug reactions .关键词
水飞蓟宾/恩替卡韦/乙型病毒性肝炎肝硬化Key words
Silibinin/Entecavir/Liver cirrhosis of hepatitis B分类
医药卫生引用本文复制引用
孙燕燕,郭英,季伟..水飞蓟宾联合恩替卡韦治疗乙型病毒性肝炎肝硬化的疗效观察[J].中国医院用药评价与分析,2017,17(12):1636-1637,1640,3.
